WhaleCreep

Avidity Partners Management LP 13F holdings, Q1 2022

Hedge fundSEC filingsCompare with another fundHoldings as of 2022-03-31, filed 2022-05-16

Avidity Partners Management LP disclosed 91 US equity positions worth $4.5bn in its Q1 2022 13F filing. Its largest position is AZN at 5.4% of the reported book, followed by ABBV and ARVN. Versus Q4 2021 it opened 19 new positions, added to 32, reduced 18 and exited 25.

$4.5bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
91
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
5.4%
Largest position
The largest single position as a share of the reported equity book.
40.9%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
38
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q4 2021: 19 new, 32 added, 18 reduced, 25 exited

50 of 91
AZN ASTRAZENECA PLCHealthcare5.4%$245m3.70m+29%added
ABBV ABBVIE INCHealthcare5.3%$238m1.47m−26%reduced
ARVN ARVINAS INCHealthcare4.4%$196m2.92m+15%added
ELV ELEVANCE HEALTH INCHealthcare4.4%$196m399,400+24%added
MRK MERCK & CO. INCHealthcare4.3%$194m2.37m–new
AVTR AVANTOR INCHealthcare4.3%$192m5.67m+18%added
BAX BAXTER INTL INCHealthcare3.3%$149m1.92m+8.5%added
ZNTL ZENTALIS PHARMACEUTICALS INCHealthcare3.3%$147m3.18m+17%added
BIOHAVEN PHARMACTL HLDG CO L no ticker–3.2%$146m1.23m+8.0%added
VRTX VERTEX PHARMACEUTICALS INCHealthcare3.2%$142m545,600+95%added
UNH UNITEDHEALTH GROUP INCHealthcare2.9%$132m259,600+111%added
UTHR UNITED THERAPEUTICS CORP DELHealthcare2.9%$129m718,946+34%added
HORIZON THERAPEUTICS PUB L no ticker–2.6%$119m1.13m+12%added
MRTXEUR MIRATI THERAPEUTICS INC–2.5%$115m1.39m+73%added
OPHTEUR IVERIC BIO INC–2.4%$109m6.48m−6.9%reduced
NBIX NEUROCRINE BIOSCIENCES INCHealthcare2.4%$109m1.16m−7.9%reduced
IOVA IOVANCE BIOTHERAPEUTICS INCHealthcare2.2%$101m6.04m+60%added
ISRG INTUITIVE SURGICAL INCHealthcare2.2%$98.0m325,000–new
CTLTEUR CATALENT INC–1.9%$86.7m782,000+13%added
HUM HUMANA INCHealthcare1.9%$86.6m198,900–new
SNDX SYNDAX PHARMACEUTICALS INCHealthcare1.9%$83.8m4.82m0.0%held
BIIB BIOGEN INCHealthcare1.7%$76.9m365,000–new
RARE ULTRAGENYX PHARMACEUTICAL INHealthcare1.4%$63.1m869,000+24%added
JNJ JOHNSON & JOHNSONHealthcare1.4%$62.7m354,000–new
ACET ADICET BIO INCHealthcare1.4%$62.3m3.12m+2.8%added
KEZAR LIFE SCIENCES INC no ticker–1.3%$58.5m3.52m+9.0%added
MCK MCKESSON CORPHealthcare1.3%$58.0m189,500–new
ARGX ARGENX SEHealthcare1.2%$55.5m176,000–new
BSX BOSTON SCIENTIFIC CORPHealthcare1.2%$53.0m1.20m–new
NTRA NATERA INCHealthcare1.2%$52.9m1.30m+38%added
EW EDWARDS LIFESCIENCES CORPHealthcare1.1%$51.8m440,000–new
ARWR ARROWHEAD PHARMACEUTICALS INHealthcare1.0%$43.9m955,000+9.1%added
IMCR IMMUNOCORE HLDGS PLCHealthcare0.9%$40.8m1.36m+11%added
LEGN LEGEND BIOTECH CORPHealthcare0.9%$39.8m1.09m+54%added
XBI SPDR SERIES TRUST–0.9%$39.5m440,000–new
BHC BAUSCH HEALTH COS INCHealthcare0.9%$38.7m1.69m–new
RNAGBP AVIDITY BIOSCIENCES INC–0.8%$37.8m2.04m+13%added
INSM INSMED INCHealthcare0.7%$31.8m1.35m−6.6%reduced
ATEC ALPHATEC HLDGS INCHealthcare0.7%$31.5m2.74m−1.3%reduced
IDYA IDEAYA BIOSCIENCES INCHealthcare0.7%$30.1m2.69m+5.4%added
CCXIEUR CHEMOCENTRYX INC–0.7%$29.5m1.18m+82%added
AXSM AXSOME THERAPEUTICS INC.Healthcare0.7%$29.4m711,000−8.3%reduced
RCUS ARCUS BIOSCIENCES INCHealthcare0.6%$28.8m912,000–new
NTLA INTELLIA THERAPEUTICS INCHealthcare0.6%$28.3m390,075–new
PHAT PHATHOM PHARMACEUTICALS INCHealthcare0.6%$26.5m1.95m+2.6%added
CRBU CARIBOU BIOSCIENCES INCHealthcare0.6%$25.9m2.82m+5.4%added
NUVB NUVATION BIO INCHealthcare0.6%$25.5m4.86m−34%reduced
BLU BELLUS HEALTH INC NEW–0.6%$25.4m3.69m−2.4%reduced
SPNEUSD SEASPINE HLDGS CORP–0.5%$24.4m2.01m0.0%held
PEN PENUMBRA INCHealthcare0.5%$23.1m104,000–new

Exited since Q4 2021

25 rows
PFE PFIZER INC2.6%$123m
ARNAEUR ARENA PHARMACEUTICALS INC2.4%$113m
LLY ELI LILLY & CO2.0%$95.2m
HO1 HOLOGIC INC1.7%$81.5m
SHC SOTERA HEALTH CO1.5%$69.7m
ALNY ALNYLAM PHARMACEUTICALS INC1.3%$62.7m
STVN STEVANATO GROUP S P A1.2%$57.1m
KYMR KYMERA THERAPEUTICS INC0.9%$42.5m
ORTHO CLINICAL DIAGNOSTICS H no ticker0.8%$38.3m
AMN AMN HEALTHCARE SERVICES INC0.7%$34.3m
GBTUSD GLOBAL BLOOD THERAPEUTICS IN0.5%$25.2m
RLMD RELMADA THERAPEUTICS INC0.3%$16.5m
ACAD ACADIA PHARMACEUTICALS INC0.1%$7.0m
TIL INSTIL BIO INC0.1%$7.0m
TALARIS THERAPEUTICS INC no ticker0.1%$7.0m
DH DEFINITIVE HEALTHCARE CORP0.1%$6.8m
EQRX INC no ticker0.1%$6.8m
GLUE MONTE ROSA THERAPEUTICS INC0.1%$6.1m
HOWL WEREWOLF THERAPEUTICS INC0.1%$5.8m
TRDA ENTRADA THERAPEUTICS INC0.09%$4.4m
SLGCUSD SOMALOGIC INC0.08%$3.8m
MERUS N V no ticker0.07%$3.3m
STTK SHATTUCK LABS INC0.03%$1.4m
TCRT ALAUNOS THERAPEUTICS INC0.01%$643k
SOMALOGIC INC no ticker0.0%$220k

Sector mix

  • Healthcare78.8%
  • Unclassified21.0%
  • Technology0.2%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters